147 related articles for article (PubMed ID: 34290904)
1. Sustained localized delivery of immunotherapy to lymph nodes reverses immunosuppression and increases long-term survival in murine glioblastoma.
Choi J; Pant A; Medikonda R; Kim YH; Routkevitch D; Saleh L; Tong L; Chan HY; Nedrow J; Jackson C; Jackson C; Lim M
Oncoimmunology; 2021; 10(1):1940673. PubMed ID: 34290904
[TBL] [Abstract][Full Text] [Related]
2. Combination checkpoint therapy with anti-PD-1 and anti-BTLA results in a synergistic therapeutic effect against murine glioblastoma.
Choi J; Medikonda R; Saleh L; Kim T; Pant A; Srivastava S; Kim YH; Jackson C; Tong L; Routkevitch D; Jackson C; Mathios D; Zhao T; Cho H; Brem H; Lim M
Oncoimmunology; 2021; 10(1):1956142. PubMed ID: 34484870
[TBL] [Abstract][Full Text] [Related]
3. Combination anti-CXCR4 and anti-PD-1 immunotherapy provides survival benefit in glioblastoma through immune cell modulation of tumor microenvironment.
Wu A; Maxwell R; Xia Y; Cardarelli P; Oyasu M; Belcaid Z; Kim E; Hung A; Luksik AS; Garzon-Muvdi T; Jackson CM; Mathios D; Theodros D; Cogswell J; Brem H; Pardoll DM; Lim M
J Neurooncol; 2019 Jun; 143(2):241-249. PubMed ID: 31025274
[TBL] [Abstract][Full Text] [Related]
4. Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas.
Zeng J; See AP; Phallen J; Jackson CM; Belcaid Z; Ruzevick J; Durham N; Meyer C; Harris TJ; Albesiano E; Pradilla G; Ford E; Wong J; Hammers HJ; Mathios D; Tyler B; Brem H; Tran PT; Pardoll D; Drake CG; Lim M
Int J Radiat Oncol Biol Phys; 2013 Jun; 86(2):343-9. PubMed ID: 23462419
[TBL] [Abstract][Full Text] [Related]
5. Synergy between glutamate modulation and anti-programmed cell death protein 1 immunotherapy for glioblastoma.
Medikonda R; Choi J; Pant A; Saleh L; Routkevitch D; Tong L; Belcaid Z; Kim YH; Jackson CM; Jackson C; Mathios D; Xia Y; Shah PP; Patel K; Kim T; Srivastava S; Huq S; Ehresman J; Pennington Z; Tyler B; Brem H; Lim M
J Neurosurg; 2022 Feb; 136(2):379-388. PubMed ID: 34388730
[TBL] [Abstract][Full Text] [Related]
6. Immunovirotherapy with measles virus strains in combination with anti-PD-1 antibody blockade enhances antitumor activity in glioblastoma treatment.
Hardcastle J; Mills L; Malo CS; Jin F; Kurokawa C; Geekiyanage H; Schroeder M; Sarkaria J; Johnson AJ; Galanis E
Neuro Oncol; 2017 Apr; 19(4):493-502. PubMed ID: 27663389
[TBL] [Abstract][Full Text] [Related]
7. CCR2 inhibition reduces tumor myeloid cells and unmasks a checkpoint inhibitor effect to slow progression of resistant murine gliomas.
Flores-Toro JA; Luo D; Gopinath A; Sarkisian MR; Campbell JJ; Charo IF; Singh R; Schall TJ; Datta M; Jain RK; Mitchell DA; Harrison JK
Proc Natl Acad Sci U S A; 2020 Jan; 117(2):1129-1138. PubMed ID: 31879345
[TBL] [Abstract][Full Text] [Related]
8. Triple combination immunotherapy with GVAX, anti-PD-1 monoclonal antibody, and agonist anti-OX40 monoclonal antibody is highly effective against murine intracranial glioma.
Jahan N; Talat H; Alonso A; Saha D; Curry WT
Oncoimmunology; 2019; 8(5):e1577108. PubMed ID: 31069135
[TBL] [Abstract][Full Text] [Related]
9. Intra-tumoral dendritic cells increase efficacy of peripheral vaccination by modulation of glioma microenvironment.
Pellegatta S; Poliani PL; Stucchi E; Corno D; Colombo CA; Orzan F; Ravanini M; Finocchiaro G
Neuro Oncol; 2010 Apr; 12(4):377-88. PubMed ID: 20308315
[TBL] [Abstract][Full Text] [Related]
10. Local Targeting of NAD
Li M; Kirtane AR; Kiyokawa J; Nagashima H; Lopes A; Tirmizi ZA; Lee CK; Traverso G; Cahill DP; Wakimoto H
Cancer Res; 2020 Nov; 80(22):5024-5034. PubMed ID: 32998997
[TBL] [Abstract][Full Text] [Related]
11. Glioblastoma Eradication Following Immune Checkpoint Blockade in an Orthotopic, Immunocompetent Model.
Reardon DA; Gokhale PC; Klein SR; Ligon KL; Rodig SJ; Ramkissoon SH; Jones KL; Conway AS; Liao X; Zhou J; Wen PY; Van Den Abbeele AD; Hodi FS; Qin L; Kohl NE; Sharpe AH; Dranoff G; Freeman GJ
Cancer Immunol Res; 2016 Feb; 4(2):124-35. PubMed ID: 26546453
[TBL] [Abstract][Full Text] [Related]
12. TIGIT and PD-1 dual checkpoint blockade enhances antitumor immunity and survival in GBM.
Hung AL; Maxwell R; Theodros D; Belcaid Z; Mathios D; Luksik AS; Kim E; Wu A; Xia Y; Garzon-Muvdi T; Jackson C; Ye X; Tyler B; Selby M; Korman A; Barnhart B; Park SM; Youn JI; Chowdhury T; Park CK; Brem H; Pardoll DM; Lim M
Oncoimmunology; 2018; 7(8):e1466769. PubMed ID: 30221069
[TBL] [Abstract][Full Text] [Related]
13. ACT001 reduces the expression of PD-L1 by inhibiting the phosphorylation of STAT3 in glioblastoma.
Tong L; Li J; Li Q; Wang X; Medikonda R; Zhao T; Li T; Ma H; Yi L; Liu P; Xie Y; Choi J; Yu S; Lin Y; Dong J; Huang Q; Jin X; Lim M; Yang X
Theranostics; 2020; 10(13):5943-5956. PubMed ID: 32483429
[TBL] [Abstract][Full Text] [Related]
14. Combined Blockade of T Cell Immunoglobulin and Mucin Domain 3 and Carcinoembryonic Antigen-Related Cell Adhesion Molecule 1 Results in Durable Therapeutic Efficacy in Mice with Intracranial Gliomas.
Li J; Liu X; Duan Y; Liu Y; Wang H; Lian S; Zhuang G; Fan Y
Med Sci Monit; 2017 Jul; 23():3593-3602. PubMed ID: 28736431
[TBL] [Abstract][Full Text] [Related]
15. Treatment of an aggressive orthotopic murine glioblastoma model with combination checkpoint blockade and a multivalent neoantigen vaccine.
Liu CJ; Schaettler M; Blaha DT; Bowman-Kirigin JA; Kobayashi DK; Livingstone AJ; Bender D; Miller CA; Kranz DM; Johanns TM; Dunn GP
Neuro Oncol; 2020 Sep; 22(9):1276-1288. PubMed ID: 32133512
[TBL] [Abstract][Full Text] [Related]
16. Agonist OX40 immunotherapy improves survival in glioma-bearing mice and is complementary with vaccination with irradiated GM-CSF-expressing tumor cells.
Jahan N; Talat H; Curry WT
Neuro Oncol; 2018 Jan; 20(1):44-54. PubMed ID: 29016879
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic targeting of tumor-associated myeloid cells synergizes with radiation therapy for glioblastoma.
Zhang P; Miska J; Lee-Chang C; Rashidi A; Panek WK; An S; Zannikou M; Lopez-Rosas A; Han Y; Xiao T; Pituch KC; Kanojia D; Balyasnikova IV; Lesniak MS
Proc Natl Acad Sci U S A; 2019 Nov; 116(47):23714-23723. PubMed ID: 31712430
[TBL] [Abstract][Full Text] [Related]
18. Preclinical investigation of combined gene-mediated cytotoxic immunotherapy and immune checkpoint blockade in glioblastoma.
Speranza MC; Passaro C; Ricklefs F; Kasai K; Klein SR; Nakashima H; Kaufmann JK; Ahmed AK; Nowicki MO; Obi P; Bronisz A; Aguilar-Cordova E; Aguilar LK; Guzik BW; Breakefield X; Weissleder R; Freeman GJ; Reardon DA; Wen PY; Chiocca EA; Lawler SE
Neuro Oncol; 2018 Jan; 20(2):225-235. PubMed ID: 29016938
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of PD-1 blockade in cervical cancer is related to a CD8
Heeren AM; Rotman J; Stam AGM; Pocorni N; Gassama AA; Samuels S; Bleeker MCG; Mom CH; Zijlmans HJMAA; Kenter GG; Jordanova ES; de Gruijl TD
J Immunother Cancer; 2019 Feb; 7(1):43. PubMed ID: 30755279
[TBL] [Abstract][Full Text] [Related]
20. Dendritic cell activation enhances anti-PD-1 mediated immunotherapy against glioblastoma.
Garzon-Muvdi T; Theodros D; Luksik AS; Maxwell R; Kim E; Jackson CM; Belcaid Z; Ganguly S; Tyler B; Brem H; Pardoll DM; Lim M
Oncotarget; 2018 Apr; 9(29):20681-20697. PubMed ID: 29755681
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
